Aida

L(+)-AP-3 L-CGG-I (5>4C3HPG S(+)-MCPA MSOP Other

ACEA-1011 Riluzole d (-)-2-Amino-7-phosphonoheptanoic acid Cii-4-phosphonomethyl-2-piperidine carboxylic acid

3-(2-Carboxypiperazin-4-yl)-propyl-l-phosphonic acid 3S,4aR,6S,8aR,-6-Phosphonomethyl-decahydroisoquinoline-3-carboxylic acid 6-(1(2)ff-Tetrazol-5-yl)methyldecahydroisoquinoline-3-carboxylic acid

6-Phosphonomethyl-decahydroisoquinoline-3-carboxylic acid 2-Amino-4,5-(1,2-cyclohexyl)-7-phosphonoheptanoic acid 2R,4R,5S-2-Amino-4, 5-(1,2-cyclohenyl)-7-phophonoheptanoic acid

5-Aza-7-chloro-4-hydroxy-3-(m-phenoxyphenyl)quinoline-2(1ff)-one 5-Nitro-6,7-dichloro-1,4-dihydro-2,3-quinoxalinedione 5-Nitro-6,7-dibromo-1,4-dihydro-2,3-quinoxalinedione 5-Nitro-6,7-dimethyl-1,4-dihydro-2,3-quinoxalinedione

1-Amino-1-cyclopropane carboxylic acid

7-Chlorokynurenic acid 6,7-Dichloroquinoxaline-2,3-dione R(+)-3-Amino-1-hydroxypyrrolidin-2-one

5-Aminocarbonyl-10,11-dihydro-5h-dibenzo[a,d]cyclohepten-5,10-imine (+)-3-Hydroxy-N-methyl morphinan

2-(2-Chlorophenyl)-2-(methylamino)-cyclohexanone 3,5-Dimethyladamantan-1-amine

(5R, 10S)-(+)-5-methyl-10,11-dihydro-5#-dibenzo[a,^cyclohepten-5,10-imine

1-(1-Phenylcyclohexyl)piperidine

N-Allyl-normetazocine

1-[1-(2-Thienyl)cyclohexyl]piperidine

(1S,2S)-1-(4-Hydroxyphenyl)-2-(4-Hydroxy-4-phenylpiperidino)-1-propanol a-(4-Chlorophenyl)-4-[(4-fluorophenyl) methyl]-1-piperidine ethanol

4-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-1-butanone

2-(4-Benzylpiperidino)-1-(4-hydroxyphenyl)-1-propanol

1-(4-Aminophenyl)-4-methyl-7,8-methylenedioxy-5_ff-2,3-benzodiazepine 1,2,3,4-Tetrahydro-6-nitro-2,3-dioxo-benzo[/]quinoxaline-7-sulfonamide

1-Aminoindan-1,5-dicarboxylic acid

2-Amino-3-phosphonopropionic acid (2S, 1'S, )-2'-(Carboxycyclopropyl)-glycine (S)-4-Carboxy-3-hydroxyphenylglycine (S)-a-Methyl-3-carboxyphenylalanine a-Methylserine-O-phosphate

5-Chloro-7-trifluoromethyl-1,2,3,4-tetrahydroquinoxaline-2,3,-dione 2-Amino-6-(trifluoromethoxy)-benzothiazole clinically unacceptable side effects, although they are generally less severe than those produced by channel blockers (11,12). In contrast, antagonists that interact with other binding sites on the NMDA receptor complex, such as the glycine and allosteric modulatory sites, tend to be associated with the fewest problematic side effects (12-14). One reason for this may be that many channel blockers act like a switch to turn the receptor "off' when the ionophore is blocked. Given the extensive

Allosteric site Glycine site: Ifenprodil

ACEA 1021 Co 101022

Ion channel site

Conquering Fear In The 21th Century

Conquering Fear In The 21th Century

The Ultimate Guide To Overcoming Fear And Getting Breakthroughs. Fear is without doubt among the strongest and most influential emotional responses we have, and it may act as both a protective and destructive force depending upon the situation.

Get My Free Ebook


Post a comment